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Abstract. – OBJECTIVE: To evaluate the abil-
ity of oral supplements with immune-stimulating 
molecules (Sambucus nigra, Zinc, Tyndallized 
Lactobacillus acidophilus (H122), Arabinogalac-
tans, vitamin D, vitamin E and vitamin C) to re-
duce the inflammation of the upper airway tract 
and improve the outcome of otitis media with ef-
fusion (OME) in children.
PATIENTS AND METHODS: Randomized con-
trolled trial. One-hundred ninety-eight children 
(CI 95%: 12-96 months) were divided into four 
groups. Group 1 (48 subjects) received 10 ml of 
oral supplements (OS) with immune-stimulat-
ing molecules for three months (20 days con-
secutively, then 10 days of suspension – the 
therapeutic scheme was repeated three times); 
Group 2 (54 children) underwent treatment with 
10 ml of OS for 90 consecutive days; Group 3 
(48 subjects) received 15 ml of OS for 45 con-
secutive days; a control group (48 children) un-
derwent the standard treatment for rhinitis and 
OME. Outcome measures included otoscopy, 
tympanometry, fibroendoscopy, and the pure 
tone audiometry (PTA) at T0 (before treatment), 
T1 (45 days after treatment), and T2 (90 days af-
ter treatment). 
RESULTS: All children treated with OS showed a 
reduction of Upper Airway Infection (UAI) episodes 
and OME compared to the control group indepen-
dent of the administration method and posology. 
The three groups treated with OS showed statis-
tically significant differences between T0 and T2 
for otoscopy, tympanometry, fibroendoscopy, and 
PTA. In Group 2, the otoscopy and the tympanom-
etry scores improved at T1. Group 2 and 3 had bet-
ter PTA results than Group 1.
CONCLUSIONS: OS with immune-stimulating 
molecules should be considered as a support-
ing therapy in children affected by recurrent ep-
isodes of UAI associated with OME due to their 
capacity to improve the immune response and 
reduce the inflammatory phenomena. OS can 
improve the fibroendoscopic findings by restor-
ing middle ear ventilation, in addition to their 
ability to reduce inflammation in the middle ear.
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ynx, Treatment supplementation.
Abbreviations
OM: Otitis Media; AOM: Acute Otitis Media; TM: 
tympanic membrane; OME: Otitis Media with Effusion; 
PTA: Pure Tone Audiometry; CHL: conductive hearing 
loss; UAI: upper airway infections; OS: Oral Supple-
ments; CG: Control Group.
Introduction
Upper Airway Infections (UAIs) are common 
in children. Due to their viral origin (rhinovirus, 
adenovirus, coronavirus), these infections do not 
respond to antibiotic treatment1 and are often 
treated with symptomatologic agents such as cor-
ticosteroids and mucolytic and anti-inflammatory 
drugs.
UAI in children under six years of age com-
monly include ear involvement due to the accu-
mulation of fluid in the middle ear (Figure 1); 
this condition, called otitis media (OM), affects 
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18% of European children2. The pathophysiology 
of OM is related to mucous ascension from the 
rhinopharynx into the middle ear due to the short 
Eustachian tube3. When mucus in the middle ear 
is inflamed due to a viral-bacterial infection, the 
OM is classified as acute (AOM); in addition, 
AOM may cause a spontaneous perforation of 
the tympanic membrane (TM). In cases with un-
infected mucus and the presence of a glue-fluid 
liquid, the OM is classified as Otitis Media with 
Effusion (OME)4,5. Both conditions may present 
a hearing deficit that is detected by pure tone 
audiometry (PTA). Hearing function is extremely 
important in children6,7 as in adults8-10; thus, every 
form of OM should be promptly treated to restore 
the functionality of the middle ear.
The standard treatment for AOM is systemic 
antibiotic therapy, corticosteroids in the form of 
nasal spray or in a saline solution suspension11,12; 
OME is usually treated with a mucolytic thera-
py associated with corticosteroids11. In children 
affected by OME with a middle-severe form of 
conductive hearing loss (CHL), the elective treat-
ment is a ventilation tube inserted into the TM to 
allow middle ear ventilation and mucus remov-
al4,11. The application of a ventilation tube has to 
Figure 1. Anatomy of the rhinopharynx, its relationship with the Eustachian tube and the normal anatomy of middle ear. In 
case of otitis media, the accumulation of mucus in the middle ear doesn’t allow a correct function of the bone chain ear with 
consequent alteration of auditory apparatus.
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be performed under general anesthesia11,13, so less 
invasive forms of treatment should be exhausted 
prior to this option. 
Currently, the success of OM treatment is 
highly variable; in fact, the resolution of this con-
dition is strictly related to the state of the upper 
airways3,4. Furthermore, young children are often 
susceptible to UAI because their immune system 
is not completely mature14. Fever and lack of 
appetite – conditions commonly associated with 
viral infections – make the children’s immune 
systems even weaker15 by establishing a chronic 
infection condition that is sometimes difficult to 
resolve. 
Some authors have proposed oral supplements 
(OS) to improve the immune response16,17. Vita-
minic oral compounds have been successfully 
used in the adult population to improve the 
immune response in patients suffering from im-
mune-deficit syndromes18 and in patients affected 
by cancer19. However, to date, the impact of OS 
on the outcomes of OME in children following 
the reduction of UAI episodes has not been 
investigated. We speculate that, by stimulating 
the immune system, it is possible to improve the 
outcomes of OM. 
The aim of this study is to test the efficacy of 
an OS that contains immune-stimulating mole-
cules (Sambucus nigra, Zinc, Tyndallized Lacto-
bacillus acidophilus (H122), Arabinogalactans, 
vitamin D, vitamin E and vitamin C) to improve 
the ventilation of middle ear and consequently the 
hearing abilities in children that suffering from 
OME in a randomized controlled trial. 
Patients and Methods
This study was conducted in the Department 
of Otolaryngology of Santobono-Pausilipon, a 
tertiary pediatric referral center, from January to 
November 2018. All procedures were approved 
by the Local Institutional Review Board Com-
mittee and were conducted in accordance with 
the Ethical principles outlined in the Declaration 
of Helsinki. The participating children’s parents 
signed a written informed consent document au-
thorizing their enrollment in the study.
Inclusion criteria were children with OME of 
different severities (from light form to glue ear) 
aged < 8 years with no previous surgery of upper 
airways and/or ear. 
Subjects were casually randomly assigned by 
the physician (single-blinded study) to one of the 
four groups: Group 1 (G1), Group 2 (G2), Group 
3 (G3), or control group (CG). G1, G2, and G3 
were treated with OS with immune-stimulating 
molecules (Sambucus nigra, Zinc, Tyndallized 
Lactobacillus acidophilus (H122), Arabinoga-
lactans, Vitamin D, Vitamin E and Vitamin C) 
(Humana Italia Spa) in combination with the 
standard treatment while CG underwent stan-
dard treatment only. The standard treatment was 
a nasal wash with Fluticasone, a mucolytic agent 
and hypertonic solution. All children started the 
treatment within two days after the first clinical 
evaluation. 
Group 1 received 10 ml of OS with the fol-
lowing posology: 10 ml for 10 consecutive days, 
followed by a 20-day of treatment suspension; 
this therapeutic scheme was repeated for three 
months consecutively. Group 2 received 10 ml 
of OS every day for 90 consecutive days; G3 re-
ceived 15 ml of OS for 45 consecutive days. 
Outcome measures included otoscopy, tym-
panometry, fibroendoscopy, and the PTA. Three 
time points were identified: T0=before treatment 
(baseline), T1=45 days after treatment with DI, 
and T2=90 days after treatment and both clinical 
evaluations and auditory tests were performed at 
each time point.
Clinical Evaluation
Children were evaluated by a pediatric oto-
laryngologist with over 10 years of experience. 
The physician evaluated their TM with a Sensera 
microscope (Zeiss, Oberkochen, Germany). The 
state of the TM was photo-recorded and then 
scored from 1 to 3 as follow: 1 = TM opaque and 
retracted, 2 = TM opaque, and 3 = healthy TM 
(Image 2a). Then, the same physician investi-
gated the state of the nose and the rhinopharynx 
using flexible fibroendoscopy (Stortz, Tuttilin-
gen, Germany) and Olympus CV-170 camera 
(Olympus, Shinjuku, Tokyo, Japan) to determine 
the presence and volume of adenoid tissue. The 
findings were classified using the Cassano assess-
ment20 with scores ranging from 1 to 4. 
Audiological Evaluation
Children’s hearing ability was evaluated with 
two tests: PTA and tympanometry. All tests 
were performed by a technician with over 20 
years of experience. PTA was performed to 
determine the auditory hearing threshold and 
the type of hearing loss (i.e., sensorineural or 
conductive) using a clinical audiometer (Madsen 
Astera, Otometrics, Taastrup, Denmark). Tym-
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panometry was performed to evaluate the sound 
transmission capacity of the middle ear using a 
Clarinet Middle Ear Analyzer (Inventis, Padua, 
Italy) (Figure 2).
The auditory threshold was scored following 
the American Speech-Language-Hearing Asso-
ciation guidelines for hearing loss with “1” 
referring to mild hearing loss (26-40 dB), “2” 
indicative of slight hearing loss (16-25 dB), 
and “3” for a typical auditory threshold (10-15 
dB). Children that showed a PTA indicative of 
sensorineural hearing loss were excluded from 
the study.
Tympanometry test produced three different 
function curves for the motility of the middle 
ear structure: tympanogram type A represented 
typical function; tympanogram type B indicated 
the presence of fluid/infection in the middle ear 
that prevented auditory transmission; and tym-
panogram type C indicated negative pressure in 
the middle ear, as in the case of a poorly func-
tioning Eustachian tube or obstruction of the 
rhinopharynx. We scored the results of the im-
mittance test as follows: 1=tympanogram type 
B, 2=tympanogram type C, 3=tympanogram 
type A (Image 2b).
Statistical Analysis 
The statistical analysis was performed by us-
ing STATA®. One-way ANOVA was used to 
evaluate the score variation within each group 
(G1, G2, G3, and CG) at the tree time points 
(T0, T1, T2) for the otoscopy findings. The same 
test was repeated to evaluate the variance of the 
tympanometry results, fibroendoscopy and PTA 
findings. 
Differences in the otoscopy findings, tympa-
nometry, fibroendoscopy, and PTA results be-
tween (and within) the four groups (G1, G2, G3, 
and CG) at T1 and at T2 were analyzed with 
one-way ANOVA. A Bonferroni-Holms ad hoc 
test was performed for each one-way ANOVA. A 
p-value < 0.05 was considered to be statistically 
significant. 
Results
Each variable’s severity in each group was 
equally distributed to guarantee the homogene-
ity of samples. Specifically, all groups included 
patients that presented PTA scores from 1 to 3 
and same for tympanometry test. In addition, the 
Figure 2. A, From left to the right the image shows the three aspect of the tympanic membrane (TM) that we considered in 
our study, respectively AOM, OME and normal aspect. B, The different shapes of the tympanometry test correlated to the 
different TM aspects. From left to right: tympanogram type B, tympanogram type C and tympanogram type A. The back 
arrow shows the maximum peak reached during the test. 
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TM and the fibroendoscopy scores were equally 
distributed in the four groups by meaning that in 
all groups were present children with TM scores 
from 1 to 3, and fibroendoscopy scores from 1 
to 4. 
All children attended correctly to the check-up 
after 45 (T1) and 90 (T2) days.
Treatment Results “within” 
Group Comparison
Figure 3 summarizes the results of the three 
groups treated with OS at the two follow-up time-
points (T1 and T2) (Figure 3).
Group 1
This group included 48 children (33 males, 
68.7%; 15 females, 31.3%) with a mean age of 5.3 
years (SD: 1.65; CI 95%: 2-8).
We observed a statistically significant improve-
ment when comparing T0, T1, and T2 in otoscopy 
(CI 95%: 1-3; ANOVA: p < 0.0001), tympanom-
etry (CI 95%: 1-3; ANOVA: p < 0.0001), fibroen-
doscopy (CI 95%: 1-4; ANOVA: p < 0.0001), and 
the PTA (CI 95%: 1-3; ANOVA: p = 0.0024).
We did not observe statistically significant 
variations for otoscopy (T1= mean: 1.8; SD: 0.6; 
CI 95%: 1-3), tympanometry (T1= mean: 1.7; SD: 
0.7; CI 95%: 1-3), fibroendoscopy (T1= mean: 2.6; 
SD: 0.8; CI 95%: 1-4), and PTA (T1= mean: 1.7; 
SD: 0.6; CI 95%: 1-3) between T0 and T1.
At T2, we identified statistically significant 
variances for the otoscopy findings (mean: 2.6; 
SD: 0.4; CI 95%: 2-3) relative to both T0 (BH: 
p < 0.01) and T1 (BH: p < 0.01). Tympanometry 
values improved (mean: 2.7; SD: 0.4; CI 95%: 2-3) 
with statistically significant scores both for T0 vs. 
T2 (BH: p < 0.01) and T1 vs. T2 (BH: p < 0.01). 
The fibroendoscopy findings ameliorated (mean: 
3.5; SD: 0,5; CI 95%: 2-4) with statistically signif-
icant p values compared to T0 (BH: p < 0.01) and 
Figure 3. The results of “within group” comparison. Two asterisks (**) represent a p value < 0.01, while one asterisk (*) 
indicates a p < 0.05. p-values are considered in function of the starting conditions (T0).
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T1 (BH: p < 0.01). Finally, PTA also significantly 
improved compared to T0 (BH: p < 0.01) and T1 
(BH: p < 0.05) (mean: 2.4; SD: 0.7; CI 95%: 2-3).
Group 2
This group included 54 subjects (39 males, 
72.2%; 15 females, 27.8%) with a mean age of 5.1 
years (SD: 1.84; CI 95%: 3-8).
We observed statistically significant improve-
ments when comparing T0, T1, and T2 for otos-
copy (CI 95%: 1-3; ANOVA: p < 0.0001), tympa-
nometry (CI 95%: 1-3; ANOVA: p < 0.0001), fi-
broendoscopy (CI 95%: 1-4; ANOVA: p < 0.0001), 
and PTA (CI 95%: 1-3; ANOVA: p < 0.0001).
The improvement between T0 and T1 was 
statistically significant for the otoscopy findings 
(mean: 1.8; SD: 0.4; CI 95%: 1-3; BH: p < 0.01) 
and tympanometry (mean: 1.7; SD: 0.5; CI 95%: 
1-3; BH: p < 0.05), while fibroendoscopy (mean: 
2.7; SD: 0.7; CI 95%: 1-4) and PTA (mean: 1.8; 
SD: 0.6; CI 95%: 1-3) variances did not reach 
scores of statistical significances.
At T2, we identified statistically significant 
variations for the otoscopy findings (mean: 2.9; 
SD: 0.2; CI 95%: 2-3) between T0 (BH: p < 0.01) 
and T1 (BH: p < 0.01). 
Tympanometry scores (mean: 2.9; SD: 0.3; CI 
95%: 2-3) improved with statistically significant 
scores both for T0 (BH: p < 0.01) and T1 (BH: p 
< 0.01). The fibroendoscopy findings (mean: 3.7; 
SD: 0.4; CI 95%: 2-4) at T2 also generated statis-
tically significant p-values compared to T0 (BH: 
p < 0.01) and T1 (BH: p < 0.01). Finally, PTA 
(mean: 2.8; SD: 0.3; CI 95% : 2-3) also improved 
significantly over T0 (BH: p < 0.01) and T1 (BH: 
p < 0.01).
Group 3
Forty-eight children were included in this 
group (27 males, 56.2%; 21 females, 43.8%) with 
a mean age of 4.6 years (SD: 1.47; CI 95%: 3-8).
We observed a statistically significant im-
provement in this group when comparing T0, T1, 
and T2 for otoscopy (CI 95%: 1-3; ANOVA: p = 
0.0032), tympanometry (CI 95%: 1-3; ANOVA: p 
= 0.0006), fibroendoscopy (CI 95%: 1-4; ANO-
VA: p < 0.0001), and PTA (CI 95%: 1-3; ANOVA: 
p = 0.0002).
We did not observe statistically significant 
variations in otoscopy (mean: 1.7; SD: 0.6 CI 
95%: 1-3), tympanometry (mean: 1.6; SD: 0.6; CI 
95%: 1-3), fibroendoscopy (mean: 2.4; SD: 0.5; CI 
95%: 1-3) and PTA (mean 1.8: SD: 0.6, CI 95%: 
1-3) between T0 and T1. 
At T2, we identified statistically significant 
differences for the otoscopy findings (mean: 2.2; 
SD: 0.6; CI 95%: 1-3) compared to T0 (BH: p 
< 0.01) and T1 (BH: p < 0.05). Tympanometry 
scores (mean: 2.2; SD:0.6; CI 95%: 1-3) improved 
with statistically significant scores relative to 
T0 (BH: p < 0.01) and T1 (BH: p < 0.05). The 
fibroendoscopy (mean: 3.3; SD: 0.5; CI 95%: 2-4) 
findings ameliorated with statistically significant 
p-values compared to T0 (BH: p < 0.01) and T1 
(BH: p < 0.01). Finally, PTA (mean: 2.5; SD: 0.5; 
CI 95%: 2-3) improved with statistically signifi-
cant values both for T0 vs. T2 (BH: p < 0.01) and 
T1 vs. T2 (BH: p < 0.01).
Control Group
This group included 48 patients (36 males, 
75%; 12 females, 25%) with an average age of 5.3 
years (SD: 1.66; CI 95%: 2-8).
We only observed statistically significant vari-
ations in the otoscopy (CI 95%: 1-3) (ANOVA: p = 
0.0032) when comparing T0 to T2 (BH: p > 0.01). 
The other outcomes [tympanometry (CI 95%: 
1-3), fibroendoscopy (CI 95%: 1-4), and PTA (CI 
95%: 1-3)] did not improve enough to reach a sta-
tistically significant level. 
Treatment Results Between 
Group Comparison at T1
Otoscopy: OS with immune-stimulating mole-
cules improved patient outcomes compared to 
the CG (ANOVA: p < 0.0001) independently 
of the administration method; specifically, we 
observed a statistically significant variation at 
T1 between G1 (mean: 1.8; SD: 0.6) and CG 
(mean: 0.6; SD: 0.8) (BH: p < 0.01), between 
G2 (mean: 1.9; SD: 0.5) and CG (BH: p < 0.01), 
and G3 (mean: 1.7; SD: 0.6) and CG (BH: p < 
0.01). No statistically significant differences 
were observed when comparing G1 and G2, G1 
and G3, and G2 and G3.
Tympanometry: OS improved patient outcome 
compared to the CG (mean: 0.5; SD: 0.9) 
(ANOVA: p < 0.0001) independent of the ad-
ministration method used; specifically, we ob-
served a statistically significant variation at T1 
between G1 (mean: 1.7; SD: 0.8) and CG (BH: 
p < 0.01), between G2 (mean: 1.7; SD: 0.5) and 
CG (BH: p < 0.01), and G3 (mean: 1.7; SD: 0.6) 
and CG (BH: p < 0.01). No statistically signif-
icant differences were revealed by comparing 
G1 and G2, G1 and G3, and G2 and G3.
Fibroendoscopy: We did not observe any statis-
tically significant variations between the four 
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groups (G1 (mean: 2.6; SD: 0.8), G2 (mean: 
2.8; SD: 0.6), G3 (mean: 2.4; SD: 0.5), and CG 
(mean: 2.4; SD: 1.1)) at T1 for this outcome.
PTA: OS treatment improved patient outcome 
compared to the CG (mean: 1.7; SD: 0.7) 
(ANOVA: p = 0.0040) but only for G3 (BH: p 
< 0.05). Furthermore, for this specific finding, 
the outcomes in G3 (mean: 2.5; SD: 0.5) were 
statistically different for G3 with G1 (mean: 
1.9; SD: 0.6) (BH: p < 0.05) and G3 with G2 
(mean: 1.8; SD: 0.6) (BH: p < 0.05). No sta-
tistically significant variations were observed 
between G1 and G2, G1 and CG, G2 and CG. 
Figure 4 summarizes the results of the out-
comes between the three groups (G1, G2, and 
G3) and the CG at T1 (Figure 4).
Group Comparison at T2
Outcome summary at T2 is shown in Figure 5 
(Figure 5). 
Otoscopy: treatment with OS improved patient 
outcome compared to the CG (ANOVA: p 
< 0.0001) independent of the administration 
method; specifically, we observed statistically 
significant variations at T2 between G1 (mean: 
2.7; SD: 0.5) and CG (mean: 0.8; SD: 1.1) (BH: 
p < 0.01), between G2 (mean: 2.9; SD: 0.2) and 
CG (BH: p < 0.01), and G3 (mean: 2.2; SD: 0.6) 
and CG (BH: p < 0.01). Statistically significant 
variances were also revealed by comparing G1 
and G3 (BH: p < 0.05) and G2 and G3 (BH: p 
< 0.01). No statistically significant differences 
were observed between G1 and G2.
Tympanometry: OS improved patient outcome 
compared to the CG (mean: 0.7; SD: 1.3) 
(ANOVA: p < 0.0001) independent of the ad-
ministration method; specifically, we observed 
a statistically significant variation at T2 be-
tween G1 (mean: 2.7; SD: 0.5) and CG (BH: p 
< 0.01), between G2 (mean: 2.9; SD: 0.3) and 
CG (BH: p < 0.01), and G3 (mean: 2.2; SD: 0.6) 
and CG (BH: p < 0.01). A statistically signifi-
cant variance was found when comparing G1 
and G3 (BH: p < 0.05) and G2 and G3 (BH: p 
< 0.01). No statistically significant differences 
were observed between G1 and G2.
Fibroendoscopy: OS treatment improved pa-
tient outcome compared to the CG (mean: 2.4; 
Figure 4. The changes observed for the four outcomes by comparing the groups of the study between T0 and after 45 days of 
treatment with oral supplements with immune-stimulating molecules (T1). Two asterisks (**) represent a p-value < 0.01, while 
one asterisk (*) indicates a p < 0.05.
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SD: 1.1) (ANOVA: p < 0.0001) independent of 
the administration method; specifically, we 
observed a statistically significant variation at 
T2 between G1 (mean: 3.6; SD: 0.5) and CG 
(BH: p < 0.01), between G2 (mean: 3.8; SD: 
0.4) and CG (BH: p < 0.01), and G3 (mean: 
3.3; SD: 0.5) and CG (BH: p < 0.01). No sta-
tistically significant differences were found 
when comparing G1 and G2, G1 and G3, and 
G2 and G3.
PTA: OS improved patient outcome compared 
to the CG (mean: 1.7; SD: 0.7) (ANOVA: p 
< 0.0001) independent of the administration 
method; specifically, we observed a statisti-
cally significant variation at T2 between G1 
(mean: 2.4; SD: 0.7) and CG (BH: p < 0.05), 
between G2 (mean: 2.8; SD: 0.4) and CG (BH: 
p < 0.01), and G3 (mean: 2.5; SD: 0.5) and CG 
(BH: p < 0.01). No statistically significant dif-
ferences were revealed by comparing G1 and 
G2, G1 and G3, and G2 and G3.
Discussion
Our results show that children with OME treat-
ed with OS with immune-stimulating molecules 
presented better outcomes compared to those 
receiving the standard treatment alone regardless 
of the administration method and posology of 
the oral supplement. The standard treatment im-
proved the fibroendoscopy findings but was not 
able to ameliorate the MT aspect, i.e., to improve 
the tympanometry results and to restore the PTA 
threshold.
Children treated with OS showed an improve-
ment in all of the four parameters investigated. 
This improvement was quite homogeneous and 
independent of the administration method and 
posology of the OS when comparing T2 to T0 
but some statistically significant differences 
between G1, G2, and G3 were present at T1 rel-
ative to T0. Furthermore, we noticed that some 
differences in the improvements when compar-
Figure 5. The changes observed for the four outcomes between the groups of the study after 90 days of treatment (T2) with 
oral supplements with immune-stimulating molecules or in case of G3 only after 90 days from the beginning of the study by 
comparing T0 vs. T2. Two asterisks (**) represent a p-value < 0.01, while one asterisk (*) indicates a p < 0.05.
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ing the study groups at T0 to T1 and at T1 to 
T2. When we singularly analyzed the variation 
(within comparison) in each group, we observed 
that children in G2 were the only ones that im-
proved in terms of otoscopy and tympanometry 
at T1, while in G1 and G3 the variation did not 
reach a statistically significant level at the same 
set-point. By comparing all four groups at T1 
(between comparison), we found that children 
in G3 were the only ones with improved PTA. 
In addition, we observed that in Group 3 at T1, 
the improvement to the MT was better than G1 
and G2. All patients treated with OS presented 
good outcomes at T2 in all of the four outcome 
measures. Subjects in Group 3 showed the best 
results of the three groups, in fact, they present-
ed with a prevalence of score 3 (highest result) 
in all four outcomes investigated. At T2, G3 
children completely resolved their OME with 
recovery in MT, tympanogram, and hearing 
thresholds with complete closure of the air-bone 
gap (indicative of CHL). Furthermore, the fibro-
endoscopy results from these patients showed 
good patency of the rhinopharynx in terms of 
the reduction of adenoid tissue hypertrophy and 
consequent improvement of middle ear venti-
lation. When we analyzed the variation within 
the same group, G2 seemed to be the optimal 
treatment regimen for obtaining a quick resolu-
tion of OME as supported by the improvement 
of otoscopy, MT, and tympanometry. However, 
when we looked at the absolute best treatment 
between the three different doses of OS and 
administration methods, the highest dosage (15 
ml) (G3) gave the best outcome. Furthermore, 
children in G3 continued to improve their out-
come by remaining the best of the three study 
groups at T2 after treatment suspension. Over-
all, our results suggest that treatment with 15 ml 
of OS fortified with phytotherapeutic extracts 
with immune-stimulating action for 45 consec-
utive days could be considered for children with 
severe forms of OME and likely even as a sup-
porting treatment for AOM. Treatment with 10 
ml for 90 consecutive days may be the best op-
tion in cases of light forms of OME or for pre-
venting inflammation of the superior airways 
and consequent OME. The immune-stimulating 
molecules in the OS administered in the study 
groups stimulate the immune system function 
21-24 by improving the white cells functions and 
by increasing the IgA in the mucus. S. nigra 
inhibits viral replication in the early stages of 
infection 25 by reducing the aggressive capac-
ity of the virus. The vitamins A, C, D, and E 
improve the response of the immune system by 
increasing mucosal IgA (A and E)26,27 and by ac-
tively stimulating macrophage and lymphocyte 
activity19,28. As with S. nigra, increased IgA 
improves the resistance of the superior upper 
airway tract to the virus25, while the improved 
activity of white blood cells (macrophages and 
lymphocytes) increases the immune response 
when the infection reaches the blood29.
Lactobacillus acidophilus presents several 
benefits on health. At first, it reduces the level 
of systemic inflammation and the concentration 
of reactive oxygen species (ROS) that depress 
the answer of the immune-system30 by inducing 
an indirect immune-stimulation; secondly, lac-
tobacillus inhibits the adhesion and the growth 
of gram-negative bacteria31 and inhibits the viral 
growth and the penetrance of virus inside the 
cells32 by protecting the subject from viral and 
bacterial aggression.
The results of immune-stimulating OS treat-
ment in children reported in this study are consis-
tent with results observed in adults15,16,18. The im-
provement in the immune response was showed 
by a reduction in the volume of the adenoid 
tissue indicative of the resolution of the infec-
tive/inflammatory process33. The decrease in the 
inflammation of the adenoid tissue acted on the 
resolution of OME by reducing the production 
of mucus and by restoring a healthy space in the 
rhinopharynx. The combination of these condi-
tions allowed for the restoration of middle ear 
ventilation4,33 and the recovery of healthy hearing 
function, as indicated by the PTA results.
Conclusions
The use of OS fortified with phytotherapeutic 
extracts with immune-stimulating action should 
be considered as a supporting therapy both for 
UAI and OME. In the present work, OS reduced 
the viral aggressiveness, improved the immune 
response, and helped the recovery process. Fur-
ther studies to evaluate the effect of OS with im-
mune-stimulating molecules directly on specific 
subsets of immune cells are necessary.
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